NYSE American · Biotechnology · USD
CEL-SCI Corporation (CVM) Stock Analysis
CEL-SCI Corporation (CVM) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CVM Key Statistics
As of Sep 4, 2026Trading
- Open
- $1.61
- Previous Close
- $1.61
- Day's Range
- 1.58–1.63
- 52-Week Range
- 0.89–11.51
- Volume
- 75.10K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.62
Valuation
- Market Cap
- $28.67M
- P/E Ratio
- unprofitable
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 1.12
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.69
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$25.41M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 17.59M
- 1-Year Return
- −85.50%
Dividend and dates
- Avg Volume
- 314.73K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
CVM Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −69.01% |
| 2025 | −56.17% |
| 2024 | −85.29% |
| 2023 | +15.74% |
| 2022 | −66.90% |
| 2021 | −39.11% |
| 2020 | +27.43% |
| 2019 | +218.82% |
| 2018 | +51.85% |
| 2017 | +8.00% |
| 2016 (partial year) | −86.54% |
As of September 4, 2026.
CVM Revenue and Earnings by Fiscal Year
FY ends September| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$25.41M | — |
| 2024 | $0.00 | −$26.92M | — |
| 2023 | $0.00 | −$32.19M | — |
| 2022 | $0.00 | −$36.70M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$24.81M | −$25.41M | — |
| 2024 | $0.00 | — | −$26.35M | −$26.92M | — |
| 2023 | $0.00 | — | −$31.48M | −$32.19M | — |
| 2022 | $0.00 | — | −$36.06M | −$36.70M | — |
Annual figures as reported, in the company's reporting currency. As of September 30, 2025.
CVM Valuation vs Biotechnology Median
Median of 656 stocks| Metric | CVM | Biotechnology median | vs median |
|---|---|---|---|
| Profit margin | 0.00% | 0.00% | 0.0 pts above |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY
BenzingaCEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B